Emergent BioSolutions Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Hello and welcome to KeyBanc's 2022 healthcare conference. My name is Harrison Schrage; I am an equity research associate on Paul Knight's life sciences team here in New York. Here, we will be discussing Emergent BioSolutions with COO, Adam Havey; and CFO, Rich Lindahl. (Conference Instructions)
Now I'll pass it off to Adam and Rich for an overview of Emergent.
Thank you, Harrison, and thank you, everybody, for participating today. I'm just going to provide a few minutes of overview just to introduce the company to you, in case you're not familiar. It starts by the fact that we are a company that develops, manufactures, and delivers protections against public health threats through a pipeline of innovative vaccines and therapeutics. We've got a growth strategy from 2020 through 2024 that we are executing against, highlighted by five key elements.
We are executing against our core business. We're looking to grow through
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
